Epinephrine and emergency medical services activation recommendations during acute allergic reactions in community settings: International consensus report.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dribin Timothy E, Sampson Hugh A, Anagnostou Aikaterini, Camargo Carlos A, Fox Adam T, Golden David B K, Michelson Kenneth A, Shaker Marcus S, Wang Julie, Alqurashi Waleed, Assa'ad Amal H, Brousseau David C, Campbell Dianne E, Campbell Ronna L, Casale Thomas B, Chu Derek K, Devonshire Ashley Lynn, Ebisawa Motohiro, Greenhawt Matthew, Lang David M, Liebermann Jay A, Leonard Stephanie, Mack Douglas P, Muraro Antonella, Neuman Mark I, Risma Kimberly A, Roberts Graham, Sargant Nicholas, Sicherer Scott H, Spergel Jonathan M, Wallace Dana, Waserman Susan, Worm Margitta, Bush Hannah R, Giambra Barbara K, Vaughn Lisa M, Kahmann Vincetta, Sobolewski Brad, Zhang Yin, Boyd Stephanie, Eftekhari Sanaz, Jaffee Hannah, Carver Melanie, Keefer Rob, Douglas Lisa, Nickels Caroline, Moore Ryan A, Schnadower David
Аннотация
OBJECTIVE: We developed consensus recommendations for administering epinephrine and activating EMS during acute allergic reactions.
METHODS: From January 2024 to May 2025, we assembled a 34-member international panel of experts to develop clinical scenarios reflecting varying severity levels within and across organ systems, candidate modifiers that may lower the threshold for epinephrine administration (eg, history of asthma), and candidate EMS activation recommendations. In phase 1, the panel engaged in a modified Delphi process to reach consensus on these outputs. In phase 2, we tested each consensus modifier by embedding it into scenarios where epinephrine was not recommended or lacked consensus, to assess potential impacts on treatment decisions.
RESULTS: The expert panel developed 24 clinical scenarios, 9 candidate modifiers, and 12 candidate EMS activation recommendations. During the first phase, 21 statements reached consensus to recommend epinephrine, 2 reached consensus not to recommend it, and 1 did not reach a consensus. There were 5 consensus modifiers and 10 consensus EMS activation recommendations. In the second phase, 2 of the 15 clinical scenarios reached consensus to recommend epinephrine administration.
CONCLUSION: We developed consensus recommendations for administering epinephrine and activating EMS during acute allergic reactions in community settings. Integrating them into technology-based decision support tools may enhance reaction management, improve patient outcomes, optimize health care utilization, and empower patient and caregiver self-efficacy.